{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:44:04Z","timestamp":1791924244874,"version":"4.3.4"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T00:00:00Z","timestamp":1639526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31901004, 81600317"],"award-info":[{"award-number":["31901004, 81600317"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint inhibitor (ICI)-associated immune-related adverse events (irAEs) are becoming important safety issues worthy of attention despite the exciting therapeutic prospects. The growing development of new ICIs also brings new cases of irAEs, raising more challenges to clinicians. Cardiac injury is rare but life-threatening among diverse organ injuries, and effective interventions are critical for patients. Here, we report a novel programmed cell death protein-1 (PD-1) inhibitor tislelizumab-associated severe myocarditis and myositis accompanied by liver and kidney damage in a ureteral urothelial\u00a0cancer patient, who was firstly treated by cardiologists because of cardiac symptoms. Due to the lack of experience about ICI-associated irAEs, an initial low-dose (0.5 mg\/kg\/day) and short-term methylprednisolone therapy was used and found to be ineffective and risky to the patient; then, steroid therapy was modulated to a higher dose (1.5 mg\/kg\/day) with prolonged\u00a0time course, and improvement of patient symptoms and laboratory\u00a0markers were observed quickly and persistently. The patient did not show adverse events under this steroid dosage. This case reports a rare tislelizumab-related myocarditis and multiple organ injuries, which provides valuable experience to cardiologists like us. Early recognition of ICI-associated myocarditis and sufficient dosage and time course of glucocorticoid therapy are critical for severe cases. High-quality clinical evidence about the precise diagnosis and therapy in ICI-associated myocarditis and other organ injuries are necessary to guide our clinical works.<\/jats:p>","DOI":"10.3389\/fimmu.2021.799077","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T10:30:08Z","timestamp":1639564208000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Case Report: Glucocorticoid Effect Observation in a Ureteral Urothelial Cancer Patient With ICI-Associated Myocarditis and Multiple Organ Injuries"],"prefix":"10.3389","volume":"12","author":[{"given":"Xiajun","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiao","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Shuai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune Checkpoint Inhibitors and Cardiovascular Toxicity","volume":"9","author":"Lyon","year":"2018","journal-title":"Lancet Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant Myocarditis With Combination Immune Checkpoint Blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"iv264","DOI":"10.1093\/annonc\/mdy162","article-title":"Management of Toxicities From Immunotherapy: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"29","author":"Haanen","year":"2018","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0012","article-title":"NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020","volume":"18","author":"Thompson","year":"2020","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"key":"B6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing Toxicities Associated With Immune Checkpoint Inhibitors: Consensus Recommendations From the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e007405","DOI":"10.1161\/CIRCHEARTFAILURE.120.007405","article-title":"Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy","volume":"13","author":"Ammirati","year":"2020","journal-title":"Circulation: Heart Failure"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4321","article-title":"Is Autoimmunity the Achilles' Heel of Cancer Immunotherapy","volume":"23","author":"June","year":"2017","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4226","article-title":"Comparative Safety of Immune Checkpoint Inhibitors in Cancer: Systematic Review and Network Meta-Analysis","volume":"363","author":"Xu","year":"2018","journal-title":"BMJ"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"New Engl J Med"},{"key":"B12","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2160-x","article-title":"The Binding of an Anti-PD-1 Antibody to FcgrI has a Profound Impact on its Biological Functions","volume":"67","author":"Zhang","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/2211-5463.13102","article-title":"Tislelizumab Uniquely Binds to the CC' Loop of PD-1 With Slow-Dissociated Rate and Complete PD-L1 Blockage","volume":"11","author":"Hong","year":"2021","journal-title":"FEBS Open Bio"},{"key":"B15","doi-asserted-by":"publisher","first-page":"15567","DOI":"10.1038\/s41598-020-72649-5","article-title":"Landscape of Immune Checkpoint Inhibitor-Related Adverse Events in Chinese Population","volume":"10","author":"Li","year":"2020","journal-title":"Sci REP-UK"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0545-2","article-title":"Treatment of Relapsed or Refractory Classical Hodgkin Lymphoma With the Anti-PD-1, Tislelizumab: Results of a Phase 2, Single-Arm, Multicenter Study","volume":"34","author":"Song","year":"2020","journal-title":"Leukemiahas a Profound Impact on Its Biological"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000437","article-title":"Tislelizumab in Chinese Patients With Advanced Solid Tumors: An Open-Label, Non-Comparative, Phase 1\/2 Study","volume":"8","author":"Shen","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14681","article-title":"Tislelizumab in Asian Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma","volume":"112","author":"Ye","year":"2021","journal-title":"Cancer Sci"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e000453","DOI":"10.1136\/jitc-2019-000453","article-title":"Phase IA\/IB Study of Single-Agent Tislelizumab, an Investigational Anti-PD-1 Antibody, in Solid Tumors","volume":"8","author":"Desai","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.666","article-title":"552p Safety and Efficacy of Long-Term Exposure (LTE) to Tislelizumab in Chinese Patients With Advanced Solid Tumour","volume":"31","author":"Shen","year":"2020","journal-title":"Ann Onc"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.664809","article-title":"Immune-Related Multiple Organs Injuries Following ICIT reatment With Tislelizumabinan Advanced Non-Small Cell Lung Cancer Patient: A CaseReport","volume":"11","author":"Deng","year":"2021","journal-title":"Front. Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa051","article-title":"Cardiovascular Magnetic Resonance in Immune Checkpoint Inhibitor-Associated Myocarditis","volume":"41","author":"Lili","year":"2020","journal-title":"Eur Heart J"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32080","article-title":"Differential Effects of Corticosteroids and Anti-TNF on Tumor-Specific Immune Responses: Implications for the Management of irAEs","volume":"145","author":"Draghi","year":"2019","journal-title":"Int J Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.1","article-title":"Immune Regulation by Glucocorticoids","volume":"17","author":"Cain","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.18502\/ijaai.v19i4.4109","article-title":"Intravenous Immunoglobulin Therapy in Myocarditis","volume":"19","author":"Mansourabadi","year":"2020","journal-title":"Iran J Allergy Asthma Immunol Nat Rev Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.799077\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T10:30:14Z","timestamp":1639564214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.799077\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,15]]},"references-count":26,"alternative-id":["10.3389\/fimmu.2021.799077"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.799077","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,15]]},"article-number":"799077"}}